Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA þ T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4
INTRODUCTION
Separation of beneficial GVL and graft-versus-infection effects from harmful graft-versus-host reactions is the Holy Grail in allogeneic hematopoietic SCT. As donor T cells are essential mediators of post transplant immunity, graft engineering techniques for removing 'bad' T cells while preserving 'good' T cells have been developed. These include selective allodepletion approaches, which specifically deplete graft-versus-host-reactive (that is, alloreactive) donor T cells upon in vitro stimulation. 1 A less complex, culture-independent approach is to eliminate donor T cells as a whole (that is, CD3) or major part (for example, CD8, TCRab) using immunomagnetic cell separation. 2, 3 Although these techniques substantially reduce alloreactive precursors and have already been successfully used to decrease the rate of severe GVHD in clinical trials, they also remove important memory T cells that protect patients from viral and fungal infections after transplantation.
Several groups, including our own, have shown that alloreactivity mainly derives from human naive compared with memory T cells, providing the rationale to deplete naive T cells from donor leukapheresis products (LPs) before clinical use. [4] [5] [6] We have also described that flow cytometry-sorted CD45RA-negative (CD45RA À ) T cells are enriched for memory cells and mediate significantly reduced alloreactive in vitro functions versus CD45RA-positive (CD45RA þ ) T cells of the same donor. 6 In the current work, we established the immunomagnetic depletion of CD45RA þ cells from entire LPs under good manufacturing practice conditions and analyzed pre-and post-depletion products for cell composition as well as for T-cell responses to pathogens and allogeneic cells.
MATERIALS AND METHODS

Collection of donor leukocytes and CD45RA depletion procedure
Six male healthy donors (median age 26 years; range 24-30 years) provided written informed consent to participate in this study, which was approved by the local ethics committee. Single leukapheresis was performed without G-CSF pre-treatment using the Cobe spectra device (Terumo BCT, Lakewood, CO, USA). LPs were depleted of CD45RA þ cells in the clean room by labeling with CliniMACS CD45RA Reagent followed by processing on the CliniMACS Plus instrument with 'DEPLETION 3.1' program (Miltenyi Biotec, Bergisch Gladbach, Germany). Aliquots of cells were cryopreserved in liquid nitrogen until use.
Flow cytometry
Flow cytometry analysis was performed on BD FACSCanto II flow cytometer with BD FACS DIVA software (BD Biosciences, Heidelberg, Germany). Residual CD45RA þ cells were measured in viable leukocytes identified by CD45 and 7-AAD staining. All MoAbs were from BD Biosciences except for FOXP3 MoAb (eBiosciences, San Diego, CA, USA). Regulatory CD4 þ T cells (T reg ) were measured by intracellular FOXP3 staining together with surface staining for CD3, CD4, CD25 and CD127.
Frequency analysis of pathogen-specific T cells by IFN-g ELISpot assay IFN-g ELISpot assays were performed as recently described. 7 Autologous immature monocyte-derived DCs 7 were pre-incubated in ELISpot plates for 6 h with CMV pp65 or EBV BZLF1 overlapping peptide pools containing CD4 þ and CD8 þ T-cell epitopes (Miltenyi Biotec), Aspergillus fumigatus lysate (Dr A Scheffold, Miltenyi Biotec), or inactivated Candida albicans germ tubes (Dr O Kurzai, Hans-Knö ll-Institute Jena, Germany), respectively. After addition of CD45RA-depleted and undepleted LP cells as responders, plates were incubated for 40 h. Spots were developed and counted using ELISpot reader ImmunoSpot Series 5 Versa (CTL, Bonn, Germany).
Detection of pathogen-specific CD4
þ and CD8 þ T cells by intracellular IFN-g staining CD45RA-depleted and undepleted LP cells were stimulated in vitro either for 6 h with CMV pp65 overlapping peptide pool or a mixture of EBV BZLF1, LMP2A, EBNA1 peptide pools (Miltenyi Biotec), or for 40 h with Candida albicans germ tubes. Golgi inhibitor monensin (BD Biosciences) was added for the last 4 or 16 h of incubation. Cells were stained for CD3, CD8, CD4 (BD Biosciences), and intracellularly with IFN-g MoAb using Inside Stain Kit (Miltenyi Biotec). Thereafter, 3 Â 10 5 events were measured on BD FACSCanto II flow cytometer with BD FACS DIVA software (BD Biosciences). Re-evaluation was performed with EXPO32 software (Beckman Coulter, Brea, CA, USA).
Detection of T-cell-mediated alloreactivity by MLRs CD45RA-depleted and undepleted LP cells were stimulated in MLRs at 1:1 ratio with irradiated (35 Gy) allogeneic PBMC derived from healthy donors with complete mismatch at HLA-A/-B/-C/-DR/-DQ loci. The HLA types of responder and stimulator cells were A*01/*32, B*39/*56, C*01/*07, DRB1*1101, DQB1*0301 and A*11/*33, B*13/*62, C*03/*06, DRB1*0401/ *1454, DQB1*0302/*0503 for LP1; A*01/*03, B*40/*50, C*02/*06, DRB1*0701/*1501, DQB1*0202/*0602 and A*02/*11, B*07/*08, C*07, DRB1*0301/*1302, DQB1*0201/*0604 for LP2; A*02/*31, B*08/*51, C*07/ *16, DRB1*0804/*0901, DQB1*0303/*0402 and A*01/*25, B*18/*40, C*12/ *15, DRB1*1404/*1601, DQB1*0502/*0503 for LP3; A*25/*26, B*18/*38, C*12, DRB1*0401, DQB1*0302 and A*03/*28, B*07/*27, C*07, DRB1*0801/ 1501, DQB1*0402/*0602 for LP4; A*03/*32, B*14/*44, C*05/*08, DRB1*0101/*0701, DQB1*0202/*0501 and A*02, B*27/*62, C*02/*03, DRB1*0401/*1454, DQB1*0302/*0503 for LP5; and A*02/*24, B*35/*44, C*04/*05, DRB1*0402/*1104, DQB1*0301/*0302 and A*11/*29, B*13/*47, C*06, DRB1*0701, DQB1*0202 for LP6; respectively. Before stimulation, fractions of CD45RA-depleted or undepleted LPs were either left unmanipulated or underwent immunomagnetic isolation of CD4 þ and CD8 þ T cells (Miltenyi Biotec). Medium was AIM-V (Gibco/Life Technologies, Darmstadt, Germany) supplemented with 5% human serum. Human IL-2 (Novartis, Basel, Switzerland) was added from d3 on at 25 IU/mL. After re-stimulation with irradiated allogeneic PBMC on d7, responder cells were tested at d12 in 20 h-IFN-g ELISpot assay for reactivity against allogeneic PBMC used for primary stimulation. To determine HLA-restriction of T-cell reactivity, MoAbs blocking the interaction of T-cell receptors with HLAclass I or II were used. 7 Statistical analysis was performed with StatView software (Version 5.0; SAS Institute, NC, USA). Residual LP samples of donors 2, 4 and 5 were stimulated in MLRs against irradiated HLA-deficient K562 cells transfected with single HLA-A*0201/-B*3503/-DQB1*0602 mismatch Ags as described 6 and were analyzed for HLA-mismatch reactivity by 20 h-IFN-g ELISpot assay.
Detection of T-cell responses to tumor-associated Ags CD45RA-depleted and undepleted LP cells (1 Â 10 6 per well) were weekly stimulated with irradiated autologous immature DCs (1 Â 10 5 per well) preloaded with 10 mg/mL Melan-A (p26-35 A27L ELAGIGILTV; JPT, Berlin, Germany) or Wilms tumor-1 peptide (p126-134 RMFPNAPYL; JPT), respectively. Human IL-7 and IL-15 (R&D Biosystems, Wiesbaden, Germany) were added at 5 ng/mL on d1, d7, and weekly thereafter. Human IL-2 (25 IU/mL) and IL-21 (10 ng/mL; Biomol, Hamburg, Germany) were weekly added from d7 on. Growing cultures were analyzed for peptide reactivity by IFN-g ELISpot assay. Figures 2 and 3) . Although most of them were CCR7
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À and CD62L À , a minor part clearly expressed both markers (Supplementary Figure 2a) . These data indicated that the CD45RA À target fraction was successfully depleted of CD45RA þ naive and late effector T cells, and contained mainly effector memory and also central memory T cells.
T-cell reactivity to common pathogens CD45RA-depleted and undepleted LPs were analyzed for pathogen-specific T-cell responses by direct in vitro stimulation with Ag preparations from CMV, EBV, Candida albicans and Aspergillus fumigatus, respectively. As both cell populations showed considerable differences in the composition of professional APCs, autologous DCs were first seeded at same numbers in IFN-g ELISpot plates and were pre-pulsed with Ags. The results showed that memory T-cell reactivity to viral and fungal Ags clearly persisted in the CD45RA-depleted subset (Figure 1 ). The median frequency of pathogen-reactive spot-forming cells in CD45RA-depleted LPs was 19 (0-285) per 10 5 CD3 þ T cells. Despite considerable variability between individual donors, cell subsets and Ags, the overall level of reactivity was in the same order of magnitude in undepleted LPs (median 15 (0-238) spot-forming cells per 10 5 ). As a result of different CD4/CD8 ratio in both fractions, pathogen reactivity was also analyzed by intracellular flow cytometry allowing co-staining of T-cell subsets and IFN-g. The data demonstrated that both CD4 þ and CD8 þ T cells significantly contributed to pathogen Ag-induced IFN-g production in CD45RA-depleted LPs (Figure 2 ). Alloreactivity in MLRs T-cell-mediated alloreactivity was measured in CD45RA-depleted and undepleted LPs of five donors by allogeneic MLR assay, in which responder and stimulator cells were mismatched for all HLA-A/-B/-C/-DR/-DQ alleles. This experimental setup was chosen to trigger the full potential of T-cell-mediated alloreactivity across MHC barriers and to avoid T-cell responses to latent viral Ags presented by shared HLA molecules, which could bias alloreactivity results. MLR responders were stimulated with allogeneic PBMC twice (d0 and d7) and were analyzed for alloreactivity on d12 by IFN-g ELISPOT assay. Figure 3a shows that the responder population of undepleted LP from donor 5 contained high numbers of alloreactive T cells, whereas reactivity to autologous PBMC was not observed. Allorecognition by undepleted LP responders could be blocked by HLA-class-I and HLA-class-II MoAbs, indicating involvement of both CD4 þ and CD8 þ T cells. In contrast, MLR cells of CD45RA-depleted LP showed strongly reduced level of alloreactivity, which was mainly mediated by persisting CD4 þ T cells (Figure 3a) . This effective reduction of alloreactive CD8
þ T cells during CD45RA depletion was also observed in four other donor LPs (P ¼ 0.016; Figure 3b , left panel).
Median percentage of alloreactive CD8
þ T cells was 0.1% (0.0-0.8%) and 6.6% (0.7-7.8%) in MLRs of CD45RA-depleted and undepleted LPs, respectively. In contrast, the proportion of alloreactive CD4
þ T cells was found at similar level following CD45RA depletion (median 4.5% (2.4-7.5%) versus 6.5% (0.1-8.5%) for CD45RA-depleted versus undepleted LPs; Figure 3c , left panel). These data were confirmed in additional MLRs on purified CD4 þ or CD8 þ T cells from both fractions (right panels of Figures  3b and c, Supplementary Figure 4) . Moreover, proliferation of MLR responders was followed until d12 and did not show significant were pre-loaded for 6 h with overlapping peptide mixes from CMV pp65 or EBV BZLF1 protein (1 mg/mL per peptide), with a lysate of Aspergillus fumigatus (40 mg/mL), or with an inactivated Candida albicans preparation (stock 10 8 germ tubes/mL, 1:300 diluted), respectively. Dose of pathogen Ags was optimal for IFN-g spot production according to previous titration experiments. CD45RA-depleted (black bars) and undepleted LP cells (grey bars) were added to ELISpot plates as responder cells. Each sample was adjusted to 1 Â 10 5 viable CD3 þ T cells per well, which was calculated from flow cytometric data after thawing. ELISpot assays were incubated for 40 h, then developed and analyzed. Data are means þ s.d. of triplicate values, and were calculated by subtraction of values from wells containing T cells and DCs without Ag (o10 spots per well; data not shown) from those with Ags. Donors were CMV-seronegative, except for donor 3. Serology data for EBV, Aspergillus and Candida were not available.
Depletion of naive T cells using CD45RA beads D Teschner et al differences between CD45RA-depleted and undepleted LPs (Supplementary Figure 5) . Residual cell aliquots of undepleted and CD45RA-depleted subsets from LP donors 2, 4 and 5 were also stimulated with K562 cells transfected with single HLA-mismatch Ags according to a previously described in vitro protocol. 6 IFN-g ELISPOT reactivity of these single-Ag-mismatch MLR responder cells on d12 showed a largely similar picture compared with that of 0/10 match MLRs, that is, CD45RA depletion resulted in reduction of CD8-mediated alloreactivity in donors 4 and 5, persistent CD8-alloreactivity in donor 2, and persistent CD4-alloreactivity in donor 5 (Supplementary Figure 6) .
T-cell reactivity to tumor-associated Ag Undepleted and CD45RA-depleted cells of LP donor 3, who was the only HLA-A*02-positive donor in this study cohort, were stimulated with autologous immature DCs pulsed with HLA-A*0201-binding peptide epitopes of tumor-associated Ag Melan-A and Wilms tumor-1, respectively. After 2 and 3 weekly restimulations, Melan-A-reactive CD8 þ T cells were observed in undepleted LP cells by IFN-g ELISpot assay (Supplementary Figure 7) . In contrast, Melan-A reactivity was not found in the CD45RA-depleted fraction. Reactivity to the Wilms tumor-1 epitope could not be detected in this donor (data not shown).
DISCUSSION
This study demonstrates that CD45RA depletion of LPs using immunomagnetic beads under clean room conditions is feasible and results in 43-log reduction of CD45RA þ T cells. Consistent with stronger CD45RA expression on CD8 þ versus CD4 þ T cells, 8 the procedure relatively increased the CD4/CD8 ratio. T cells in final products were predominantly of CD45RA À effector memory and central memory phenotype, whereas those of CD45RA þ naive or late effector differentiation were completely removed. 9 The total number of T cells in depleted products was high enough to be used as donor leukocyte infusions (DLIs), and is expected to increase with donor age because of the expanding memory T-cell compartment. Interestingly, CD45RA depletion also eliminated CD45RA þ naive CD4 þ T reg cells, which comprise 20-30% of entire T reg cells in young adults with steadily decreasing numbers during Depletion of naive T cells using CD45RA beads D Teschner et al life-time. 10 Whether lack of CD45RA þ T reg cells will adversely affect the in vivo ability to control GVHD needs detailed exploration in clinical trials.
CD45RA-depleted LPs contained CD4 þ and CD8 þ T cells with intact functional in vitro activity against CMV, EBV, Aspergillus and Candida Ags. The partial preservation of both major T-cell subsets during depletion is a clear advantage over alternative strategies based on the elimination of entire CD8 þ or TCRab T cells.
2,3
Therefore, CD45RA-depleted DLIs should accelerate the reconstitution of CD4 þ and CD8 þ T-cell immunity to pathogens, which might translate into lower infection-related morbidity and mortality after allogeneic hematopoietic SCT. 11 The use of CD45RA À memory T cells in adoptive immunotherapy could also circumvent the technically much more complex and pathogen-restricted ex vivo selection of pathogen-specific donor T cells by HLA-peptide multimers or cytokine secretion assays. 12, 13 The absolute numbers of pathogen-reactive IFN-g spot-forming cells were overall not increased in CD45RA
-memory T cells compared with original LPs. Potential reasons for this observation are the depletion-induced variation in CD4/CD8 ratio as well as the removal of late effector T cells. We observed that a median of 12.3 (6.2-28.6) % CD8 þ T cells in undepleted LPs co-expressed CD45RA and CD45RO, which phenotypically represented late effector T cells 9 that were completely eliminated after CD45RA depletion. As this cell subset contained minor but consistent numbers of IFN-gsecreting pathogen-specific CD8 þ T cells (data not shown), the CD45RA depletion strategy might decrease the overall magnitude of antiviral and antifungal T-cell responses. However, it is CD45RA-depl.
CD45RA-depl.
CD45RA-depl. þ or CD4 þ T cells seeded per well. The latter counts were calculated from flow cytometric measurement on MLR responder cells directly before adding them to ELISpot plates. Mann-Whitney U-test was used to calculate P-values on wells with alloreactivity in undepleted versus CD45RA-depleted LPs.
Depletion of naive T cells using CD45RA beads D Teschner et al reasonable to assume that such late effector T cells will again reconstitute from CD45RA À central and effector memory T cells after adoptive transfer into patients in vivo.
9
CD45RA depletion effectively decreased the number of alloreactive CD8 þ T cells by median 41-log according to MLRs using stimulator cells without any matched HLA allele. In contrast, alloreactive CD4 þ T cells were found at similar numbers after CD45RA depletion. This appears contradictory to our previous study, where significant reduction of alloreactivity was observed in flow cytometry-sorted CD45RA À CD8 þ as well as in CD45RA À CD4 þ T cells. 6 However, the previous MLR assays measured alloreactivity of purified T cells to single HLA-mismatch Ags, whereas the current ones used a relatively heterogeneous mixture of beads-separated responder cells and stimulator cells from completely HLA-mismatched donors. The difference between the previous and current MLR results might also be explained by the role of bystander cells in both fractions, for example, by APCs or by T reg cells, which are activated by matched HLA molecules.
14 As in vitro stimulation against completely HLA-mismatched cells reflected an artificial condition with regard to the clinical situation, additional MLR assays were performed in single-HLA Ag-mismatch design using K562-HLA transfectants. 6 Here we observed a similar picture compared with results from 0/10-match MLRs, albeit with lower degree in the reduction of alloreactivity upon CD45RA depletion.
The stronger residual alloreactivity in CD45RA-depleted CD4 þ than CD8 þ T cells might also be explained by less stringent rules of peptide binding to HLA-class-II molecules and T-cell receptor recognition by CD4 þ T cells, resulting in more promiscuous (allo)-reactivity in the CD4 þ subset. 15 As memory T cells have the capacity of rapid expansion upon secondary Ag challenge, the formation of alloreactive memory T cells could have serious consequences in terms of GVHD. Presensitization would be a particular problem if pathogen-specific T cells with cross-reactivity to alloantigens are triggered by encounter with infectious agents. 16, 17 Nevertheless, reduced GVHD rates after CD8-depleted DLIs 3 and absent HLA-class-II expression on non-hematopoietic cells under non-inflammatory conditions 18 suggest that CD45RA depletion, albeit less effective in CD4 þ T cells, may decrease the overall GVHD potential of donor leukocytes in vivo.
Antitumor reactivity could only be analyzed for tumorassociated Ag Melan-A in donor 3 and showed that Melan-Areactive CD8 þ T cells mainly resided in undepleted LP repleted with naive T cells. 19 Although these data are of relatively low significance because of the small sample size, they are consistent with previous results of several investigators including ourselves showing that naive-depleted (or memory-enriched) CD8 þ T cells contained very low numbers of leukemia-reactive T cells, 6, [20] [21] [22] [23] regardless which T-cell differentiation marker including CD45RA was used for cell selection. This suggests the use of CD45RA-depleted DLIs preferentially in situations where the risk of leukemia relapse is low or the disease is nonmalignant. However, a potential antitumor reactivity of CD45RA-depleted cells needs further evaluation since such effects have been described for memory T cells by others in vitro and in mouse models. 24 In case of high risk of leukemia relapse, alternative strategies focusing on leukemia reactivity within memory T cells should be considered, such as using donors with natural alloimmunity or vaccinating them with leukemia Ags. 25 Also replenishment of DLIs with in vitro produced leukemia-reactive T cells from the CD45RA þ naive-enriched T-cell subset may be an option. [21] [22] [23] In conclusion, clinical grade depletion of naive T cells from entire LPs is feasible and highly efficient using magnetic CD45RA beads and the CliniMACS device. The CD45RA À target fraction contains effector and central memory T cells that show preserved reactivity to common viral and fungal pathogens. T-cell-mediated alloreactivity was reduced in CD45RA À cells, with much stronger efficacy in the CD8 þ than CD4 þ subset. We are currently preparing a multi-center pilot trial to test CD45RA-depleted DLIs in the clinical situation. Data of this preclinical study suggest two major risk-adapted strategies: prophylactic infusions appear suitable to accelerate CD4 þ and CD8 þ T-cell reconstitution after allogeneic hematopoietic SCT, thereby preventing opportunistic infections. Furthermore, the preemptive or therapeutic use could be appropriate when post transplant infections are severe or occur repetitively, particularly if selection of Ag-specific donor T cells by HLA-peptide multimers and cytokine-secretion assays is not available. Infection-related inflammation may trigger CD4 þ T-cell-mediated alloreactivity by means of upregulated HLAclass-II expression. It might therefore be considered to additionally deplete CD4
þ T cells in case of active infection at the time of DLI. The latter could be accomplished by subsequent positive selection of CD8 þ T cells with clinical grade beads, 3 which appears feasible given 410 8 CD8 þ T cells in CD45RA-depleted LPs. Clinical data are required to determine if CD45RA depletion of DLIs results in improved outcome with regard to infections, GVHD and disease relapse.
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